KCM
VRTX icon

Kennedy Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kennedy Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
22,838
-156
-0.7% -$69.1K 0.2% 180
2026
Q1 		$10.3M Buy
22,994
+580
+3% +$270K 0.22% 171
2025
Q4 		$10.2M Buy
22,414
+234
+1% +$101K 0.22% 163
2025
Q3 		$8.69M Buy
22,180
+2,770
+14% +$1.16M 0.19% 189
2025
Q2 		$8.64M Sell
19,410
-1,047
-5% -$482K 0.21% 170
2025
Q1 		$9.92M Sell
20,457
-3,158
-13% -$1.47M 0.24% 146
2024
Q4 		$9.51M Buy
23,615
+10,084
+75% +$4.67M 0.21% 146
2024
Q3 		$6.29M Buy
13,531
+1,540
+13% +$740K 0.14% 257
2024
Q2 		$5.62M Buy
11,991
+3,680
+44% +$1.6M 0.12% 288
2024
Q1 		$3.47M Buy
+8,311
New +$3.51M 0.07% 409

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kennedy Capital Management's VRTX Position: Q2 2026 in Review

Kennedy Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.68% in Q2 2026, selling an estimated $69.1K and leaving 22,838 shares worth $11.3M. The position accounts for 0.2% of the portfolio, ranked #180.

Kennedy Capital Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Kennedy Capital Management held 22,838 shares of Vertex Pharmaceuticals worth $11.3M as of Q2 2026.
  • Kennedy Capital Management sold 156 Vertex Pharmaceuticals shares in Q2 2026, an estimated $69.1K.
  • Vertex Pharmaceuticals made up 0.2% of Kennedy Capital Management's portfolio in Q2 2026, its #180 holding.
  • Kennedy Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.